2 completed, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow pegvisomant: new trials by email Literature Review of pegvisomant trials Research Report on pegvisomant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects 1 x 30 mg/mL pegvisomant, 2 x 15 mg/mL pegvisomant - Healthy Volunteers | Phase 1 | Completed | Pfizer | 17 | 2013-08-01 | 2013-12-12 |
| Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects pegvisomant - Bioavailability | Phase 1 | Completed | Pfizer | 14 | 2010-10-01 | 2012-01-05 |
| Figitumumab Combined With Pegvisomant For Advanced Solid Tumors figitumumab, pegvisomant - Colorectal Neoplasms, Lung Neoplasms | Phase 1 | Terminated | Pfizer | 24 | 2009-11-01 | 2013-12-13 |
Breast Neoplasms (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Prostatic Neoplasms (1) · Sarcoma (1)
Pfizer (3)
Belgium (1) · Canada (1) · Finland (1) · Germany (1) · Singapore (1) · United States (1)